Fatigue and cognitive complaints are the most prevalent and burdensome symptoms among females with prolactinoma, regardless of disease control status.
Active prolactinoma, defined by elevated prolactin levels, is associated with significantly higher anxiety, depression, and overall disease burden compared to controlled prolactinoma.
Despite effective prolactin normalization in nearly all patients using dopamine agonists, symptom burden remains substantial, underscoring unmet therapeutic and rehabilitative needs.
